LungQ Software

by Thirona  · Based in Netherlands → — Experts in AI-Powered lung image analysis Advancing pulmonary precision medicine
Pulmonology Radiology

Contact-for-pricing
Regulatory Status Disclosed

Overview

Thirona’s LungQ® software offers advanced, AI-powered analysis of thoracic CT scans, providing comprehensive quantitative insights for the detection, evaluation, and treatment planning of various lung diseases. Leveraging deep learning models, LungQ® performs high-fidelity segmentation and quantification of anatomical structures within the lungs, including lobes, segments, subsegments, airways, blood vessels, and fissures.

The software delivers reproducible CT values for pulmonary tissue, which is crucial for objective support in diagnosis, patient selection for treatment, and longitudinal monitoring of disease progression and treatment efficacy. LungQ® analyses extend to detailed airway morphology (identifying bronchial wall thickness, dilatation, narrowing, and mucus impaction), vascular morphology (assessing pulmonary arterial and venous volume changes), and parenchymal analysis (characterizing texture patterns and estimating chronic perfusion defects, known as PXT).

Recent versions, such as LungQ® 4, have expanded capabilities to include enhanced peripheral airway segmentation, estimation of chronic perfusion defects from CT, and post-treatment detection of endobronchial implants. This technology is designed to support physicians in making more precise diagnoses, personalizing treatment strategies, guiding interventional procedures like bronchoscopy, and accelerating respiratory clinical trials.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis of thoracic CT scans
  • Automated segmentation of pulmonary segments and subsegments
  • Volumetric analysis and quantification of anatomical structures
  • Airway morphology analysis (bronchial wall thickness, dilatation, narrowing, mucus impaction)
  • Vascular morphology analysis (pulmonary arterial and venous volume changes)
  • Fissure completeness analysis
  • Parenchymal analysis (texture patterns, estimated chronic perfusion defects - PXT)
  • Post-treatment detection of endobronchial implants
  • Provides reproducible CT values for pulmonary tissue
  • One-page report with severity scores for emphysematous lung tissue and fissure completeness

Use Cases

  • Diagnosis and evaluation of lung diseases
  • Treatment planning for lung interventions (e.g., lung volume reduction, bronchoscopy)
  • Follow-up and longitudinal monitoring of disease progression
  • Respiratory clinical trials and drug development
  • Patient phenotyping and selection for personalized medicine
  • Guidance for navigational bronchoscopy

What Physicians Need to Know

Key Capabilities
LungQ software offers AI-powered analysis of thoracic CT scans, providing quantitative measurements of anatomical volumes, disease distribution, airway morphology, vascular morphology, and fissure completeness. It can quantify bronchial dilation, wall thickening, mucus plug volume and location, and pulmonary blood volume distribution. The software also provides high-resolution segmentation of anatomy and pathological features across lobar, segmental, and subsegmental levels. LungQ 4, a recent version, includes enhanced peripheral airway segmentation, estimation of chronic perfusion defects from CT (PXT), and post-treatment detection of endobronchial implants. It also features LungQ® AVX for quantifying vessel diameters and volumes in pulmonary arteries and veins.
Clinical Utility
LungQ aids in the detection, evaluation, and treatment planning of lung diseases, supporting personalized procedural planning, real-time guidance, and longitudinal follow-up. It helps in identifying treatment targets, assessing patient eligibility, and pre-operative planning of virtual bronchoscopy pathways. The software is useful for managing conditions like COPD, emphysema, bronchiectasis, severe asthma, cystic fibrosis, and lung cancer. It provides reproducible CT values for pulmonary tissue, essential for quantitative support in diagnosis and follow-up examinations. LungQ can also assist in assessing mucus burden changes in response to treatment. The PXT feature supports treatment target selection in lung volume reduction therapy.
Integration Options
LungQ modules are designed for flexible integration into diverse workflows and can be integrated into early R&D, interventional systems, and clinical workflows. It is available through AI marketplaces or distribution platforms, and can be deployed locally on dedicated hardware. Thirona has partnered with Blackford Platform to offer LungQ to healthcare providers.
Compliance Status
Thirona is MDR compliant and operates under ISO 13485 certification. LungQ has received FDA 510(k) clearance for multiple versions, including LungQ 3.0.0 and LungQ 4. It is also approved for clinical use in Europe, the UK, and Australia. LungQ version 5, including automated mucus plug analysis (LungQ® MP), has obtained CE marking as a Class IIb medical device under the EU Medical Device Regulation (EU) 2017/745 (MDR).
Pricing Model
The pricing model for LungQ is not specified but is based on the number of analyses. Pricing information is available upon request from the provider.
User Experience
LungQ is designed to be intuitive and user-friendly, bridging the gap between academic developments and clinical usability. It supports physicians in the diagnosis, evaluation, and documentation of pulmonary tissue images. The software provides a one-page report with severity scores and visual representation of abnormal tissue for easy interpretation.
Implementation Complexity
The software can be deployed locally on dedicated hardware. It is a stand-alone command-line software that must be run from a command-line interpreter and does not have a graphical user interface.
Evidence Base
LungQ's algorithms are trained on deeply characterized phenotypic datasets to ensure robustness across disease severity, scan quality, and anatomical complexity. The technology is extensively validated across diseases and patient populations. Thirona states that LungQ 3.0.0 builds on 10 years of clinical trials and over 200 publications. Studies have shown LungQ's ability to provide accurate disease progression management with consistent and reproducible measurements. Clinical evaluations have confirmed that PXT delivers quantitative information comparable to SPECT-CT.
Physician Tip

When using LungQ, pay close attention to the quantitative measurements provided for bronchial dilation, wall thickening, mucus plugs, and pulmonary blood volume distribution, as these can offer precise insights beyond visual assessment. Leverage the enhanced peripheral airway segmentation for more accurate planning of bronchoscopic interventions, especially for distal targets. Utilize the PXT feature for patient selection and treatment planning in lung volume reduction therapies. For longitudinal follow-up, the software's ability to track changes over time can be invaluable for assessing disease progression and treatment response. Remember that while the software provides detailed analysis, clinical correlation with patient symptoms and other diagnostic findings remains crucial for comprehensive patient care.

LungQ is designed for flexible integration into existing clinical workflows and systems, including interventional systems and research and development environments. It is available through AI marketplaces and distribution platforms, such as the Blackford Platform. Deployment is typically local on dedicated hardware. While it operates as a command-line interface, its modular design allows for adaptability across various use cases and therapeutic areas.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact-for-pricing
DeploymentSoftware solution, designed for integration into clinical workflows and systems.
Compliance
BAA Available No AI-estimated
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
SOC 2 No AI-estimated
Integrations
EHR Not specified
Specialties Pulmonology, Radiology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2018-06-05K173821 510(k)LungQ Software

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate LungQ Software

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for LungQ Software.

View all on YouTube

Frequently Asked Questions

LungQ Software provides AI-powered analysis of thoracic CT scans, offering quantitative insights for comprehensive assessment of lung anatomy and diseased regions. It aids in precise identification of anatomical structures and disease patterns, supporting diagnosis, treatment planning, and follow-up examinations for conditions like lung cancer.
LungQ Software has received FDA 510(k) clearance in the United States, with version 3.0.0 cleared in early 2024 and version 4 cleared in late 2025. It is also approved for clinical use in Europe, the UK, and Australia. Thirona, the developer of LungQ, states that its quality and compliance philosophy is built on a certified Quality Management System (ISO 13485) and adheres to international frameworks for medical-device software and data governance regulations, ensuring data protection and reliability.
While AI in lung cancer diagnosis shows promise, limitations include model generalizability, transparency, and the need for external validation. AI-assisted reading can improve sensitivity for detecting nodules but may decrease specificity, potentially leading to more false positives and unnecessary follow-ups. Most AI models are trained on single-institution or homogeneous datasets, which can limit their applicability to diverse patient populations or different imaging protocols.
LungQ is designed for flexible integration into diverse workflows. AI software for lung analysis, in general, is often integrated into PACS workstations, allowing for seamless blending into the existing clinical workflow with minimal disruption. This integration can provide radiologists with a 'second opinion' and aid in streamlining the workflow.
Yes, several other AI solutions exist for lung cancer screening and nodule analysis. These include products from companies like Siemens Healthineers (syngo.via CT Lung CAD), Contextflow (SEARCH Lung CT), GE Healthcare, Coreline Soft (AVIEW LCS), Riverain Technologies, Vuno, Qure.ai, Aidoc, Carpl.ai, and ScreenPoint Medical. These alternatives offer various features such as automated nodule detection, characterization, volumetric analysis, and integration with PACS and EHR systems.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

More in the LungQ line

LungQ LungQ Software (this page)

More from Thirona

LungQ
Thirona
Radiology & Imaging AI
LungQ by Thirona offers AI-powered analysis of thoracic CT scans for specialized clinical care and interventional pulmonology, providing quantitative support for diagnosis, treatment planning, and follow-up examinations of lung diseases.
RetCAD
Thirona
Ophthalmology AI
RetCAD is a CE-certified AI software product from Thirona that analyzes color fundus images for the presence of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR), aiding in early detection and grading of these vision-threatening conditions.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-14 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.